Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JATT NASDAQ:LXEO NASDAQ:NMRA NASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJATTJATT Acquisition$10.32-1.5%$9.54$9.99▼$11.31$82.82MN/A8,240 shs166 shsLXEOLexeo Therapeutics$4.87+11.4%$5.52$3.60▼$10.99$377.52M1.39914,123 shs949,417 shsNMRANeumora Therapeutics$0.89-49.9%$1.97$0.72▼$3.65$168.79M2.741.57 million shs10.71 million shsPRLDPrelude Therapeutics$4.57+1.7%$4.31$0.75▼$5.54$365.95M1381,091 shs127,791 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJATTJATT Acquisition0.00%-0.43%-1.90%+67.26%+760.00%LXEOLexeo Therapeutics0.00%0.00%-14.15%-33.49%+10.91%NMRANeumora Therapeutics0.00%+9.20%-3.26%-37.98%+110.78%PRLDPrelude Therapeutics0.00%+17.85%+0.22%+33.63%+367.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJATTJATT Acquisition$10.32-1.5%$9.54$9.99▼$11.31$82.82MN/A8,240 shs166 shsLXEOLexeo Therapeutics$4.87+11.4%$5.52$3.60▼$10.99$377.52M1.39914,123 shs949,417 shsNMRANeumora Therapeutics$0.89-49.9%$1.97$0.72▼$3.65$168.79M2.741.57 million shs10.71 million shsPRLDPrelude Therapeutics$4.57+1.7%$4.31$0.75▼$5.54$365.95M1381,091 shs127,791 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJATTJATT Acquisition0.00%-0.43%-1.90%+67.26%+760.00%LXEOLexeo Therapeutics0.00%0.00%-14.15%-33.49%+10.91%NMRANeumora Therapeutics0.00%+9.20%-3.26%-37.98%+110.78%PRLDPrelude Therapeutics0.00%+17.85%+0.22%+33.63%+367.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJATTJATT Acquisition 0.00N/AN/AN/ALXEOLexeo Therapeutics 2.88Moderate Buy$20.14313.61% UpsideNMRANeumora Therapeutics 2.56Moderate Buy$7.67760.46% UpsidePRLDPrelude Therapeutics 2.40Hold$7.6767.91% UpsideCurrent Analyst Ratings BreakdownLatest JATT, NMRA, LXEO, and PRLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LXEOLexeo Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/4/2026PRLDPrelude Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/1/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026PRLDPrelude Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/28/2026PRLDPrelude Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/27/2026PRLDPrelude Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.004/21/2026NMRANeumora Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJATTJATT AcquisitionN/AN/A$0.38 per share27.08($0.53) per shareN/ALXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$0.62 per shareN/APRLDPrelude Therapeutics$12.14M29.95N/AN/A$1.09 per share4.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/ALXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)NMRANeumora Therapeutics-$236.93M-$1.33N/AN/AN/AN/A-181.70%-119.15%8/5/2026 (Estimated)PRLDPrelude Therapeutics-$99.50M-$1.00N/AN/AN/AN/A-118.24%-66.12%8/13/2026 (Estimated)Latest JATT, NMRA, LXEO, and PRLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PRLDPrelude Therapeutics-$0.27-$0.13+$0.14-$0.13$4.58 million$4.58 million5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/7/2026Q1 2026NMRANeumora Therapeutics-$0.32-$0.30+$0.02-$0.30N/AN/A3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/A3/30/2026Q4 2025NMRANeumora Therapeutics-$0.34-$0.35-$0.01-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJATTJATT AcquisitionN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJATTJATT AcquisitionN/A0.150.15LXEOLexeo TherapeuticsN/A14.1614.16NMRANeumora Therapeutics0.755.095.09PRLDPrelude TherapeuticsN/A2.032.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJATTJATT Acquisition47.97%LXEOLexeo Therapeutics60.67%NMRANeumora Therapeutics47.65%PRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipJATTJATT Acquisition20.00%LXEOLexeo Therapeutics2.00%NMRANeumora Therapeutics26.94%PRLDPrelude Therapeutics49.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJATTJATT Acquisition38.03 million13.80 millionNot OptionableLXEOLexeo Therapeutics5878.52 million76.95 millionNot OptionableNMRANeumora Therapeutics108185.28 million135.37 millionOptionablePRLDPrelude Therapeutics12079.64 million40.46 millionOptionableJATT, NMRA, LXEO, and PRLD HeadlinesRecent News About These CompaniesPrelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comEarnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 16, 2026 | finance.yahoo.comPrelude Therapeutics (PRLD) price target increased by 11.49% to 7.01May 14, 2026 | msn.comPrelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline UpdateMay 12, 2026 | quiverquant.comQPrelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 12, 2026 | globenewswire.comWall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a BetMay 8, 2026 | zacks.comD Boral Capital initiates coverage of Prelude Therapeutics (PRLD) with buy recommendationMay 5, 2026 | msn.comPrelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast CancerMay 1, 2026 | uk.finance.yahoo.com9 Best Biotech Penny Stocks to Buy in 2026April 30, 2026 | insidermonkey.comPrelude Therapeutics (PRLD) price target increased by 19.35% to 6.29April 29, 2026 | msn.comPrelude Therapeutics director David P. Bonita acquires $12.5 million in stockApril 24, 2026 | investing.comInsider Buying: Prelude Therapeutics (NASDAQ:PRLD) Director Acquires 2,815,315 Shares of StockApril 24, 2026 | insidertrades.comPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at ...April 20, 2026 | finance.yahoo.comPrelude Therapeutics prices $90M equity offeringApril 20, 2026 | seekingalpha.comPrelude Therapeutics Announces Pricing of $90.0 Million Underwritten OfferingApril 20, 2026 | globenewswire.comPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026April 20, 2026 | globenewswire.comPrelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical OfficerApril 15, 2026 | globenewswire.comWhy Prelude Therapeutics Incorporated’s (PRLD) Stock Is Up 7.34%April 7, 2026 | aaii.comAWhy Prelude Therapeutics Incorporated’s (PRLD) Stock Is Up 8.79%March 31, 2026 | aaii.comAPrelude Therapeutics (PRLD) price target increased by 29.17% to 5.27March 28, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJATT, NMRA, LXEO, and PRLD Company DescriptionsJATT Acquisition NYSE:JATT$10.32 -0.16 (-1.53%) As of 06/12/2026 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Lexeo Therapeutics NASDAQ:LXEO$4.87 +0.50 (+11.44%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Neumora Therapeutics NASDAQ:NMRA$0.89 -0.89 (-49.94%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Prelude Therapeutics NASDAQ:PRLD$4.57 +0.08 (+1.69%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
